Douglas Galasko on End of the RoAD for Gantenerumab? Roche Declares Prodromal Alzheimer’s Trial Futile
COMMENT Futility analysis has the potential to save unnecessary cost and participant exposure to a medication that does not work, and is a useful tool in clinical trials. For Alzheimer's disease, where the progression of pathology and clinical measures is co